Recent studies suggest that modulating REV‐ERBα activity can be a potent therapeutic target for neurodegenerative disease such as AD via modulating the glia activity and neuroinflammation response (Griffin et al., 2019; Roby et al., 2019). The gene discussed is NR1D1; the disease is Alzheimer disease.